[1]
|
Roffifi, M., Patrono, C., et al. (2016) ESC Guidelines for the Management of Acute Coronary Sindrome in Patients Pre-senting without Persistent ST-Segment Elevation. European Heart Journal, 37, 267-315.
https://doi.org/10.1093/eurheartj/ehv320
|
[2]
|
Roe, M.T., Armstrong, P.W., Fox, K.A., et al. (2012) Prasugrel ver-sus Clopidogrel for Acute Coronary Syndromes without Revascularization. The New England Journal of Medicine, 367, 1297-1309.
|
[3]
|
Podda, G.M., Grossi, E., Palmerini, T., et al. (2017) Prediction of High On-Treatment Platelet Reactiv-ity in Clopidogrel-Treated Patients with Acute Coronary Syndromes. International Journal of Cardiology, 240, 60-65.
https://doi.org/10.1016/j.ijcard.2017.03.074
|
[4]
|
Hochholzer, W., Trenk, D., Bestehorn, H.P., et al. (2006) Impact of the Degree of Peri-Interventional Platelet Inhibition after Loading with Clopidogrel on Early Clinical Outcome of Elec-tive Coronary Stent Placement. Journal of the American College of Cardiology, 48, 1742-1750. https://doi.org/10.1016/j.jacc.2006.06.065
|
[5]
|
Al Awaida, W., Ahmed, A.A., Hamza, A.A., et al. (2021) Associa-tion of KDR rs1870377 Genotype with Clopidogrel Resistance in Patients with Post Percutaneous Coronary Intervention. Heliyon, 7, e06251.
https://doi.org/10.1016/j.heliyon.2021.e06251
|
[6]
|
Wang, T., Li, H., Wang, F., et al. (2021) The Effects of Poly-morphisms in CYP2C19, ATP-Binding Cassette Transporter B1, and Paraoxonase-1 on Clopidogrel Treatment of Uygur Patients Following Percutaneous Coronary Intervention. European Journal of Clinical Pharmacology, 77, 1679-1686. https://doi.org/10.1007/s00228-021-03176-z
|
[7]
|
Akkaif, M.A., Daud, N.A.A., Sha’aban, A., et al. (2021) The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD). Molecules, 26, 1987.
https://doi.org/10.3390/molecules26071987
|
[8]
|
Bouman, H.J., Schomig, E., van Werkum, J.W., et al. (2011) Paraoxonase-1 Is a Major Determinant of Clopidogrel Efficacy. Nature Medicine, 17, 110-116. https://doi.org/10.1038/nm.2281
|
[9]
|
Su, J., Li, J., Yu, Q., et al. (2019) Association of PON1 Gene Promoter DNA Methylation with the Risk of Clopidogrel Resistance in Patients with Coronary Artery Disease. Journal of Clinical Laboratory Analysis, 33, e22867.
https://doi.org/10.1002/jcla.22867
|
[10]
|
Sun, Y., Lu, Q., Tao, X., et al. (2020) Cyp2C19∗2 Polymorphism Related to Clopidogrel Resistance in Patients with Coronary Heart Disease, Especially in the Asian Population: A Systematic Re-view and Meta-Analysis. Frontiers in Genetics, 11, Article ID: 576046. https://doi.org/10.3389/fgene.2020.576046
|
[11]
|
Galeazzi, R., Olivieri, F., Spazzafumo, L., et al. (2018) Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. Drugs Aging, 35, 649-656.
https://doi.org/10.1007/s40266-018-0555-1
|
[12]
|
Zhang, J., Dong, Z.F., Bian, C.X., et al. (2022) The Correlation between MDR1 Gene Polymorphism and Clopidogrel Resistance in People of the Hui and Han Nationalities. Clinical and Applied Thrombosis/Hemostasis, 28.
https://doi.org/10.1177/10760296211073272
|
[13]
|
Wang, K., Yuan, Y., Cho, J.H., et al. (2012) Comparing the Mi-croRNA Spectrum between Serum and Plasma. PLOS ONE, 7, e41561. https://doi.org/10.1371/journal.pone.0041561
|
[14]
|
Stokanovic, D., Nikolic, V.N., Konstantinovic, S.S., et al. (2016) Pglycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concen-tration. Pharmacology, 97, 101-106.
https://doi.org/10.1159/000442712
|
[15]
|
Su, Q., Li, J., Tang, Z., et al. (2019) Association of CYP2C19 Polymor-phism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China. Medical Science Monitor, 25, 7138-7148.
https://doi.org/10.12659/MSM.915971
|
[16]
|
Zhang, Y., Shi, X.-J., Peng, W.-X., et al. (2021) Impact of Imple-menting CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients after Percutaneous Coronary Intervention: A Real-World Study in China. Frontiers in Pharmacology, 11, Article ID: 582929.
https://doi.org/10.3389/fphar.2020.582929
|
[17]
|
Brown, S.-A. and Pereira, N. (2018) Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. Journal of Personalized Medicine, 8, 8. https://doi.org/10.3390/jpm8010008
|
[18]
|
Tabari, R.G., Marjani, A., Ataby, O.A., et al. (2013) Genetic Poly-morphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. Oman Medical Journal, 28, 237-244. https://doi.org/10.5001/omj.2013.69
|
[19]
|
Alhazzani, A.A., Munisamy, M., Karunakaran, G., et al. (2017) Phar-macogenetics of CYP2C19 Genetic Olymorphism on Clopidogrel Response in Patients with Ischemic Stroke from Saudi Arabia. Neurosciences (Riyadh), 22, 31-37.
https://doi.org/10.17712/nsj.2017.1.20160303
|
[20]
|
Tang, X.F., Wang, J., Zhang, J.H., et al. (2013) Effect of the CYP2C19 2 and 3 Genotypes, ABCB1 C3435T and PON1 Q192R Alleles on the Pharmacodynamics and Adverse Clinical Events of Clopidogrel in Chinese People after Percutaneous Coronary Intervention. European Journal of Clinical Pharmacology, 69, 1103-1112.
https://doi.org/10.1007/s00228-012-1446-8
|
[21]
|
Zou, J.J., Xie, H.G., Chen, S.L., et al. (2013) Influence of CYP2C19 Loss-of-Function Variants on the Antiplatelet Effects and Cardiovascular Events in Clopidogrel-Treated Chi-nese Patients Undergoing Percutaneous Coronary Intervention. European Journal of Clinical Pharmacology, 69, 771-777. https://doi.org/10.1007/s00228-012-1392-5
|
[22]
|
Zheng, L., Yang, C., Xiang, L. and Hao, Z. (2019) Gen-otype-Guided Antiplatelet Therapy Compared with Conventional Therapy for Patients with Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Biomarkers, 24, 517-523. https://doi.org/10.1080/1354750X.2019.1634764
|
[23]
|
Zhang, M., Wang, J.R., Zhang, Y., et al. (2020) Effects of Individualized Antiplatelet Therapy Based on CYP2C19 Genotype and Platelet Function on the Prognosis of Patients af-ter PCI. European Review for Medical and Pharmacological Sciences, 24, 10753-10768. https://doi.org/10.1177/0267659120978584
|
[24]
|
Soran, H., Schofield, J.D., Liu, Y. and Durrington, P.N. (2015) How HDL Protects LDL against Atherogenic Modification: Paraoxonase 1 and Other Dramatis Personae. Current Opinion in Lipidology, 26, 247-256.
https://doi.org/10.1097/MOL.0000000000000194
|
[25]
|
Chistiakov, D.A., Melnichenko, A.A., Orekhov, A.N. and Bobryshev, Y.V. (2017) Paraoxonase and Atherosclerosis-Related Cardiovascular Diseases. Biochimie, 132, 19-27. https://doi.org/10.1016/j.biochi.2016.10.010
|
[26]
|
Farid, N.A., Kurihara, A. and Wrighton, S.A. (2010) Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans. The Jour-nal of Clinical Pharmacology, 50, 126-142.
https://doi.org/10.1177/0091270009343005
|
[27]
|
Primo-Parmo, S.L., Sorenson, R.C., Teiber, J. and La Du, B.N. (1996) The Human Serum Paraoxonase/Arylesterase Gene (PON1) Is One Member of a Multigene Family. Genomics, 33, 498-507. https://doi.org/10.1006/geno.1996.0225
|
[28]
|
Ohmori, T., Yano, Y., Sakata, A., et al. (2012) Lack of Association between Serum Paraoxonase-1 Activity and Residual Platelet Aggregation during Dual Anti-Platelet Therapy. Thrombosis Research, 129, e36-e40.
https://doi.org/10.1016/j.thromres.2011.10.033
|
[29]
|
Mbatchi, L.C., Gassiot, M., Pourquier, P., Goberna, A., Ma-hammedi, H., Mourey, L., Joly, F., Lumbroso, S., Evrard, A. and Houede, N. (2017) Association of NR1I2, CYP3A5 and ABCB1 Genetic Polymorphisms with Variability of Temsirolimus Pharmacokinetics and Toxicity in Patients with Metastatic Bladder Cancer. Cancer Chemotherapy and Pharmacology, 8, 1-7. https://doi.org/10.1007/s00280-017-3379-5
|
[30]
|
Ghosh, C., Hossain, M., Solanki, J., Najm, I.M., Marchi, N. and Janigro, D. (2017) Overexpression of Pregnane X and Glucocorticoid Receptors and the Regulation of Cytochrome P450 in Human Epileptic Brain Endothelial Cells. Epilepsia, 58, 576-585. https://doi.org/10.1111/epi.13703
|
[31]
|
Castaño, G., Burgueño, A., Fernández Gianotti, T., Pirola, C.J. and Sookoian, S. (2010) The Influence of Common Gene Variants of the Xenobiotic Receptor (PXR) in Genetic Susceptibility to Intrahepatic Cholestasis of Pregnancy. Aliment. Pharma-cology & Therapeutics 31, 583-592. https://doi.org/10.1111/j.1365-2036.2009.04210.x
|
[32]
|
Wu, Y., Yu, H., Tang, H.Q., et al. (2018) PXR Polymorphisms Have Impact on the Clinical Efficacy of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Gene, 653, 22-28.
https://doi.org/10.1016/j.gene.2018.02.022
|
[33]
|
Hechler, B. and Gachet, C. (2015) Purinergic Receptors in Thrombosis and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 2307-2315. https://doi.org/10.1161/ATVBAHA.115.303395
|
[34]
|
Li, J.L., Fu, Y., Qin, S.B., et al. (2018) Association between P2RY12 Gene Polymorphisms and Adverse Clinical Events in Coronary Artery Disease Patients Treated with Clopidogrel: A Systematic Review and Meta-Analysis. Gene, 657, 69-80. https://doi.org/10.1016/j.gene.2018.03.007
|
[35]
|
Zoheir, N., Abd Elhamid, S., Abulata, N., et al. (2013) P2Y12 Receptor Gene Polymorphism and Antiplatelet Effect of Clopidogrel in Patients with Coronary Artery Disease after Cor-onary Stenting. Blood Coagulation & Fibrinolysis, 24, 525-531. https://doi.org/10.1097/MBC.0b013e32835e98bf
|
[36]
|
Jneid, H., Addison, D., Bhatt, D.L., et al. (2017) 2017 AHA/ACC Clinical per Formance and Quality Measures for Adults with ST-Elevation and Non-ST-Elevation Myocardi-al Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Journal of the American College of Cardiology, 70, 2048-2090. https://doi.org/10.1161/HCQ.0000000000000032
|
[37]
|
Faggioni, M., Baber, U., Chandrasekhar, J., et al. (2019) Use of Prasugrel vs Clopidogrel and Outcomes in Patients with and without Diabetes Mellitus Presenting with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. International Journal of Cardiology, 275, 31-35. https://doi.org/10.1016/j.ijcard.2018.10.071
|
[38]
|
Yaseen, I.F., Farhan, H.A. and Abbas, H.M. (2019) Clopidogrel Non-Responsiveness in Patients Undergoing Percutaneous Coronary Intervention Using the Verify Now Test: Frequen-cy and Predictors. European Journal of Hospital Pharmacy, 26, 113-116.
|
[39]
|
Ferreiro, J.L. and Angiolillo, D.J. (2011) Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation, 123, 798-813. https://doi.org/10.1161/CIRCULATIONAHA.109.913376
|
[40]
|
Sternisha, S.M. and Miller, B.G. (2019) Molecular and Cellular Regulation of Human Glucokinase. Archives of Biochemistry and Biophysics, 663, 199-213. https://doi.org/10.1016/j.abb.2019.01.011
|
[41]
|
Mohawk, J.A., Green, C.B. and Takahashi, J.S. (2012) Central and Peripheral Circadian Clocks in Mammals. Annual Review of Neuroscience, 35, 445-462. https://doi.org/10.1146/annurev-neuro-060909-153128
|
[42]
|
Laing, E.E., Johnston, J.D., Moller-Levet, C.S., et al. (2015) Exploiting Human and Mouse Transcriptomic Data: Identification of Circadian Genes and Pathways Influencing Health. BioEssays, 37, 544-556.
https://doi.org/10.1002/bies.201400193
|
[43]
|
Morris, C.J., Purvis, T.E., Hu, K. and Scheer, F.A. (2016) Circadian Misalignment Increases Cardiovascular Disease Risk Factors in Humans. Proceedings of the National Academy of Sci-ences of the United States of America, 113, E1402-E1411. https://doi.org/10.1073/pnas.1516953113
|
[44]
|
Hermida, R.C., Ayala, D.E., Mojón, A. and Fernández, J.R. (2010) Influence of Circadian Time of Hypertension Treatment on Cardiovascular Risk: Results of the MAPEC Study. Chronobiology International, 27, 1629-1651.
https://doi.org/10.3109/07420528.2010.510230
|
[45]
|
Liu, D., Song, J., Ji, X., et al. (2016) Association of Genetic Polymorphisms on VEGFA and VEGFR2 with Risk of Coronary Heart Disease. Medicine, 95, e3413. https://doi.org/10.1097/MD.0000000000003413
|
[46]
|
Zhang, L.-J., Zhang, Y.-Q., Han, X., et al. (2016) Associa-tion of VEGFR-2 Gene Polymorphisms with Clopidogrel Resistance in Patients with Coronary Heart Disease. American Journal of Therapeutics, 23, e1663-e1670.
https://doi.org/10.1097/MJT.0000000000000231
|